Form 8-K - Current report:
SEC Accession No. 0000886163-20-000116
Filing Date
2020-10-30
Accepted
2020-10-30 16:07:37
Documents
15
Period of Report
2020-10-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20201026.htm   iXBRL 8-K 37945
2 EX-3.1 exhibit31-ligandxfourt.htm EX-3.1 163185
  Complete submission text file 0000886163-20-000116.txt   383217

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20201026.xsd EX-101.SCH 2430
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lgnd-20201026_cal.xml EX-101.CAL 718
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lgnd-20201026_def.xml EX-101.DEF 1655
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20201026_lab.xml EX-101.LAB 25277
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20201026_pre.xml EX-101.PRE 13195
8 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20201026_htm.xml XML 11277
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 201277388
SIC: 2834 Pharmaceutical Preparations